

Immunotherapy I: Targeting Checkpoint, Co-Stimulatory and Novel Immunomodulatory MOAs



Immunotherapy I: Targeting Checkpoint, Co-Stimulatory and Novel Immunomodulatory MOAs


Moderator:

Jeff Bockman, PhD, VP, Defined Health

Panelists:

- *Ada Braun, MD, PhD, Chief Medical Officer, Biothera*
- *Axel Hoos, MD, PhD, VP, Oncology Research and Development, GlaxoSmithKline*
- *Johanna Joyce, PhD, Member, Memorial Sloan Kettering Cancer Center*
- *Hy Levitsky, MD, Adjunct Professor, Oncology, Medicine and Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine*
- *Nils Lonberg, PhD, SVP, Biologics Discovery, Bristol-Myers Squibb*
- *Harlan Robins, PhD, Co-Founder and Chief Scientific Officer, Adaptive Biotechnologies*
- *Jedd Wolchok, MD, PhD, Ludwig Center at Memorial Sloan Kettering Cancer Center*

Cancer cells are highly mutated



Immunotherapy I: Targeting Checkpoint, Co-Stimulatory and Novel Immunomodulatory MOAs

Moderator:

Jeff Bockman, PhD, VP, Defined Health

Panelists:

- *Ada Braun, MD, PhD, Chief Medical Officer, Biothera*
- *Axel Hoos, MD, PhD, VP, Oncology Research and Development, GlaxoSmithKline*
- *Johanna Joyce, PhD, Member, Memorial Sloan Kettering Cancer Center*
- *Hy Levitsky, MD, Adjunct Professor, Oncology, Medicine and Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine*
- *Nils Lonberg, PhD, SVP, Biologics Discovery, Bristol-Myers Squibb*
- *Harlan Robins, PhD, Co-Founder and Chief Scientific Officer, Adaptive Biotechnologies*
- *Jedd Wolchok, MD, PhD, Ludwig Center at Memorial Sloan Kettering Cancer Center*